Precision for Medicine Acquires EganLee, Expands Foothold in the Asia-Pacific (APAC) market
We are excited to announce that EganLee, an Australian-based firm providing a range of clinical trial services for the pharmaceutical, biotechnology, medical device and CRO industries has joined the Precision family! With strong, established relationships with numerous AsiaPac research sites, the acquisition of EganLee expands Precision’s clinical trial footprint in AsiaPac.
Precision Value & Health Acquires Global Omnichannel Engagement Leader, Across Health
EU-based team brings a unique omnichannel optimization platform and digital transformation capabilities to leading life-sciences companies
BETHESDA, MD—March 24, 2021—Precision Value & Health, the industry leader for commercialization services for innovative life science companies, today announced that it has acquired Across Health. Across Health is a leading global omnichannel engagement consultancy focused on providing clients an analytical and evidence-based framework for commercial strategy, execution, and resource optimization. The company’s solutions are based around its proprietary, market-leading Navigator365 product suite, which more than 40 pharmaceutical companies rely on for omnichannel planning and resource allocation. The Across Health team is already working hand-in-hand with Precision’s medical communications, creative, and data sciences teams to offer analytically driven launch and commercialization programs across the product life cycle.
Conference Videos: Gene Therapy for Rare Disorders 2021
How To Calculate Viral Vector Yields: A Critical Component Of The “Make vs Buy” Analysis
Calculating viral vector yields is essential to determine how much drug product is needed for a specific gene therapy. It’s a critical analysis for any gene therapy organization looking to scale from preclinical to clinical to commercial. Project Farma’s Tony Khoury, Christian Hermanas and Salome Philip provide an in depth review of a valuable yield calculation tool that can serve as a vital prerequisite of the “make vs buy” analysis.
Taking On The Talent Crunch In Biopharma, Cell & Gene Manufacturing
Although clinical trials in the cell and gene therapy space have skyrocketed, there’s a significant shortfall in the skilled talent required to execute on the exponential potential of cell and gene therapies. Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury discuss the biotherapeutic process and manufacturing talent gap, and propose a multipronged approach to addressing the problem through internal innovation and the external influence of academia and industry associations.